Trial Profile

A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Navitoclax (Primary) ; Ruxolitinib (Primary) ; Danazol; Fedratinib; Hydroxycarbamide; Peginterferon alfa-2a
Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
Focus Registrational; Therapeutic Use
Acronyms TRANSFORM-2
Sponsors AbbVie; AbbVie Germany

24 Apr 2025 The protocol has been amended to addition in treatment Arm C.
16 Jan 2025 Planned End Date changed from 29 Jan 2025 to 1 Dec 2026.
16 Jan 2025 Planned primary completion date changed from 29 Jan 2025 to 1 Feb 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com